Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.
Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.
复制标题
DOI:
10.1021/acs.jmedchem.2c00539
复制
发表时间:
2022-09-22
影响因子:
7.3
通讯作者:
Li, Guangfu
中科院分区:
文献类型:
--
作者:
Cheng, Kun;Fetse, John;Zhao, Zhen;Liu, Hao;Mamani, Umar-Farouk;Mustafa, Bahaa;Adhikary, Pratik;Ibrahim, Mohammed;Liu, Yanli;Patel, Pratikkumar;Nakhjiri, Maryam;Alahmari, Mohammed;Li, Guangfu
Blockade of the interaction between programmed cell death ligand-1 (PD-L1) and its receptor PD-1 has shown great success in cancer immunotherapy. Peptides possess unique characteristics that give them significant advantages as immune checkpoint inhibitors. However, unfavorable physicochemical properties and proteolytic stability profiles limit the translation of bioactive peptides as therapeutic agents. Studies have revealed that cyclization improves the biological activity and stability of linear peptides. In this study, we report the use of macrocyclization scanning for the discovery of cyclic anti-PD-L1 peptides with improved bioactivity. The cyclic peptides demonstrated up to a 34-fold improvement in the PD-1/PD-L1 blocking activity and significant in vivo anti-tumor activity. Our results demonstrate that macrocyclization scanning is an effective way to improve the serum stability and bioactivity of the anti-PD-L1 linear peptide. This strategy can be employed in the optimization of other bioactive peptides, particularly those for protein-protein interaction modulation.
登录
查看更多内容
影响因子:
10.9
作者:
Gong J;Chehrazi-Raffle A;Reddi S;Salgia R
通讯作者:
Salgia R
影响因子:
3.8
作者:
Chen, Ke;Huang, Liuliu;Shen, Bin
通讯作者:
Shen, Bin
影响因子:
7.3
作者:
Kumar, Anil;Ye, Guofeng;Parang, Keykavous
通讯作者:
Parang, Keykavous
影响因子:
10.9
作者:
Liu, Hao;Zhao, Zhen;Cheng, Kun
通讯作者:
Cheng, Kun
影响因子:
100.3
作者:
Beck, Alain;Wurch, Thierry;Corvaia, Nathalie
通讯作者:
Corvaia, Nathalie